Minneapolis Heart Institute Foundation announced it has enrolled the first-in-the-world patient in a clinical study to evaluate a minimally invasive clip-based repair system made by Abbott for treating people with moderate or severe tricuspid regurgitation (TR). This study is the first application of this minimally invasive technology for use in the tricuspid heart valve, where currently there are no options for most patients. Paul Sorajja, M.D., performed this first-in-human procedure at Minneapolis Heart Institute at Abbott Northwestern Hospital.

Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company CorAssist in a 72-year-old diastolic heart failure patient.

Multi-Level CTO Course (ML CTO)

Critical Limb Ischemia Course (CLIC)

International Medical Center (IMC) LIVE

Abbott announced it has initiated a U.S. pivotal clinical study evaluating the safety and effectiveness of a modified version of its Amplatzer device designed to correct patent ductus arteriosus (PDA), a common congenital heart defect.

Recent Advances in the Management of Valvular Heart Disease

September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE Trial presented in a Hot Line LBCT Session at ESC Congress. Rates of bleeding were similar between the two groups.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now